In the U.S. it is approved for HER2+ BC in adjuvant therapy (with anthracyclines and taxane) and for metastatic HER2+ BC in monotherapy or in combination with chemotherapeutics, tyrosine kinase inhibitors (TKIs), and immunotherapy. This evidence concerns the gene ERBB2 and breast cancer.